Prior Expectations for Hims Stock
Hims & Hers Health had been viewed as a promising player in the telehealth and wellness sector, with expectations for growth fueled by a robust business model and increasing consumer demand. The company had posted impressive annual sales of $2.35 billion and demonstrated a strong year-to-date share price return of -52.89%. Investors were optimistic, particularly given the company’s three-year total shareholder return, which was positive and outperformed the one-year total shareholder return of 56.22%.
Decisive Changes and Immediate Impact
However, a decisive moment occurred when Hims & Hers Health faced significant regulatory challenges. The FDA tightened rules on compounded GLP-1 drugs, which directly affected the company’s operations. On February 9, 2026, Hims & Hers Health’s shares plunged by 22% in response to these pressures, marking a stark contrast to the previous optimism surrounding the stock. This decline was compounded by the company’s decision to pull its semaglutide pill after legal threats from both Novo Nordisk and the FDA.
Direct Effects on Hims & Hers Health
The immediate effects of these developments have been profound. Hims & Hers Health’s share price has more than halved over the last 12 months, reflecting the market’s reaction to the regulatory landscape. Despite these challenges, the company reported a 49% increase in Q3 revenue, reaching $599 million, and its subscriber base expanded by 21% to 2.5 million users. Furthermore, adjusted EBITDA jumped 53% to $78.4 million, indicating that while the stock performance has suffered, the underlying business fundamentals remain strong.
Expert Perspectives on the Shift
Experts have weighed in on the situation, noting that the regulatory pressure specifically targets compounded GLP-1 drugs, which could create a competitive moat for Novo Nordisk if they succeed in eliminating copycat products. This shift in the competitive landscape has raised concerns among investors regarding Hims & Hers Health’s future growth potential. Despite the challenges, some analysts remain bullish, highlighting that Hims & Hers Health is not merely a telehealth gimmick but is becoming a crucial infrastructure layer for healthcare in the United States.
Market Sentiment and Technical Indicators
Market sentiment has also shifted dramatically. Following the news of the regulatory changes, Reddit traders have increased discussions about Hims & Hers Health, with sentiment scores reaching 88, indicating a very bullish outlook among retail investors. However, technical indicators reveal oversold conditions, with the Relative Strength Index (RSI) collapsing to 23.71, well below the typical threshold of 30 that signals a potential reversal.
Uncertainties Ahead
Looking forward, uncertainties loom over Hims & Hers Health’s trajectory. The impact of regulatory changes on the company’s future growth remains unclear, and the long-term effects of the partnership with Novo Nordisk are uncertain. Details remain unconfirmed, leaving investors and analysts to navigate a complex landscape as they assess the company’s potential recovery and growth strategies.
